demonstrated that intracellular PD-L1 regulates the DDR by binding and stabilizing the mRNAs of DNA damage genes, and a novel PD-L1 antibody, H1A, can sensitize cancer to DNA-damaging therapy, radiation or chemotherapy, by promoting PD-L1 degradation (172). Here, CD274 is linked to cancer.